Pfizer Must Correct Data Integrity Problems Seen At India Plant Globally, FDA Says
Executive Summary
US FDA warning letter instructed Pfizer to implement a global corrective and preventive action plan to address widespread data integrity problems. While the impact of the warning letter on the site is expected to be minimal due to its closure, the global impact on the company’s sterile drug operations could be significant.
You may also be interested in...
Pfizer India Site Slammed By FDA
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
FDA Warning Letter Slams Pfizer Site In India On Sterility Testing, Environmental Monitoring
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes
Legislative proposal in FY 2020 budget request wouldn't necessarily reduce number of complete response letters, but ability to require reports and postmarket changes on quality issues might eventually create more flexibility during initial product reviews.